Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)

NCT05883644 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05883644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05883644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 27, 2023
Completion date
December 30, 2026
Enrollment
111 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma